

A Medscape **LIVE!** EVENT

The Evolving Treatment Landscape of NF1-Associated Tumors

Exploring the Use of MEK Inhibitors **CME**

SUNDAY, MAY 31, 2020 | 5:00 PM – 6:00 PM EDT

 VIRTUAL EVENT



FACULTY



Jaishri Blakeley, MD

Professor of Neurology, Neurosurgery, and Oncology
The Marjorie Bloomberg Tiven Professor of Neurofibromatosis
Johns Hopkins University
School of Medicine
Director, Neurofibromatosis Therapeutic Acceleration Program
Director, Johns Hopkins Comprehensive Neurofibromatosis Program
Director, Johns Hopkins UCNS Neuro-Oncology Fellowship
Baltimore, Maryland

Participation by Dr Blakeley does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.



Michael Jay Fisher, MD

Professor of Pediatrics
University of Pennsylvania
Perelman School of Medicine
Chief, Neuro-Oncology Section
Director, Neurofibromatosis Program
Hubert J.P. and Anne Faulkner Schoemaker Endowed Chair in Pediatric Neuro-Oncology
Center for Childhood Cancer Research and Division of Oncology
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania

TARGET AUDIENCE

This activity is intended for neuro-oncologists, neurologists, neurosurgeons, and pediatricians.

LEARNING OBJECTIVES

Upon completion of this activity, participants will:

- Have increased knowledge regarding the
 - Rationale for MEK inhibitor use in the management of neurofibromatosis type 1 (NF1)-associated tumors
 - Recent data from clinical trials evaluating MEK inhibitors in the management of NF1-associated tumors

Have greater competence related to

- Managing adverse events in patients receiving MEK inhibitors for the management of NF1-associated tumors

Demonstrate greater confidence in their ability to

- Integrate clinical trial data into practice for the treatment of patients with NF1-associated tumors

ACCREDITATION STATEMENT

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education



For Physicians

Medscape, LLC designates this live activity for a maximum of 1.0 **AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AGENDA

5:00 PM
Introduction
Jaishri Blakeley, MD

5:05 PM
NF1-Associated Plexiform Neurofibromas
Jaishri Blakeley, MD

5:10 PM
NF1-Associated Optic Pathway Gliomas
Michael Jay Fisher, MD

5:20 PM
MEK Inhibitors for NF1-Associated Plexiform Neurofibromas and Low-Grade Gliomas
Michael Jay Fisher, MD

5:30 PM
MEK Inhibition: Now and in the Future
Jaishri Blakeley, MD

5:40 PM
Case Studies
Jaishri Blakeley, MD
Michael Jay Fisher, MD

5:50 PM
Audience Q&A

6:00 PM
Conclusion

www.medscape.org/symposium/nf1